Company intelligence / Profile preview
MitoImmune Therapeutics
Seoul, South Koreamitoimmune.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MitoImmune Therapeutics Inc. is a clinical-stage biotech company developing small molecule drugs that target mitochondrial dysfunction to treat necrotic and inflammatory diseases. Its lead candidate, MIT‑001, has reached Phase II trials for oral mucositis prevention in head and neck cancer patients receiving chemoradiotherapy. The company also has multiple preclinical assets targeting conditions such as liver cirrhosis, idiopathic pulmonary fibrosis, Friedreich ataxia, Alzheimer’s disease, and macular dystrophy. The company leverages proprietary technology focused on modulating mitochondria-driven inflammation and cell death pathways.
- Therapeutic areas
- GastroenterologyPulmonologyOphthalmologyOncologyNeurology
- Modalities
- Small moleculesChemical drugs
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on MitoImmune Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MitoImmune Therapeutics.